Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 1, 2015, Pages 103-111

  Goldberg, Terry E ^a   Harvey, Philip D ^b,c   Wesnes, Keith A ^d   Snyder, Peter J ^e   Schneider, Lon S ^f  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Wesnes Cognition ^*  (United Kingdom)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Clinical trials; Cognition; Neuropsychology; Practice effects; Preclinical Alzheimer's disease; Serial assessment

Indexed keywords

EID: 84938683855     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2014.11.003     Document Type: Article

References (48)

1. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122.
2. Goldberg T.E., Keefe R.S., Goldman R.S., Robinson D.G., Harvey P.D. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 2010, 35:1053-1062.
3. Pietrzak R.H., Snyder P.J., Maruff P. Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects. Schizophr Res 2010, 124:176-182.
4. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
5. Kozauer N., Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 2013, 368:1169-1171.
6. Budson A.E., Price B.H. Memory dysfunction. N Engl J Med 2005, 352:692-699.
7. Wesnes K., Pincock C. Practice effects on cognitive tasks: a major problem?. Lancet Neurol 2002, 1:473.
8. Thorndike E.L., Woodworth R.S. The influence of movement in one mental function upon the efficiency of other functions. Psychol Rev 1901, 8:247-261.
9. Kelly A.M., Garavan H. Human functional neuroimaging of brain changes associated with practice. Cereb Cortex 2005, 15:1089-1102.
10. Duff K., Lyketsos C.G., Beglinger L.J., Chelune G., Moser D.J., Arndt S., et al. Practice effects predict cognitive outcome in amnestic mild cognitive impairment. Am J Geriatr Psychiatry 2011, 19:932-939.
11. Dodge H.H., Wang C.N., Chang C.C., Ganguli M. Terminal decline and practice effects in older adults without dementia: the MoVIES project. Neurology 2011, 77:722-730.
12. Meinert C.L., Breitner J.C. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2008, 4(1 Suppl 1):S7-S14.
13. Calamia M., Markon K., Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol 2012, 26:543-570.
14. Eagger S., Morant N., Levy R., Sahakian B. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects. Br J Psychiatry 1992, 160:36-40.
15. Galasko D., Abramson I., Corey-Bloom J., Thal L.J. Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer's disease. Neurology 1993, 43:1559-1563.
16. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998, 50:136-145.
17. Birks J., Harvey R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006, CD001190.
18. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998, 158:1021-1031.
19. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005, 352:2379-2388.
20. Bartels C., Wegrzyn M., Wiedl A., Ackermann V., Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010, 11:118.
21. Rabbitt P., Diggle P., Smith D., Holland F., Mc Innes L. Identifying and separating the effects of practice and of cognitive ageing during a large longitudinal study of elderly community residents. Neuropsychologia 2001, 39:532-543.
22. Krenk L., Rasmussen L.S., Siersma V.D., Kehlet H. Short-term practice effects and variability in cognitive testing in a healthy elderly population. Exp Gerontol 2012, 47:432-436.
23. Frank R., Wiederholt W.C., Kritz-Silverstein D.K., Salmon D.P., Barrett-Connor E. Effects of sequential neuropsychological testing of an elderly community-based sample. Neuroepidemiology 1996, 15:257-268.
24. Wesnes K.A., Schneider L.S. Are neuropsychological tests such as those used in ADNI suitable for long-term trials of cognition enhancers for preclinical Alzheimer's disease?. J Nutr Health Aging 2012, 16:810.
25. Salthouse T.A., Tucker-Drob E.M. Implications of short-term retest effects for the interpretation of longitudinal change. Neuropsychology 2008, 22:800-811.
26. Machulda M.M., Pankratz V.S., Christianson T.J., Ivnik R.J., Mielke M.M., Roberts R.O., et al. [Formula: see text]Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging. Clin Neuropsychol 2013, 27:1247-1264.
27. Harvey P.D., Reichenberg A., Bowie C.R., Patterson T.L., Heaton R.K. The course of neuropsychological performance and functional capacity in older patients with schizophrenia: Influences of previous history of long-term institutional stay. Biol Psychiatry 2010, 67:933-939.
28. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007, 64:633-647.
29. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-682.
30. Beglinger L.J., Gaydos B., Tangphao-Daniels O., Duff K., Kareken D.A., Crawford J., et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol 2005, 20:517-529.
31. Harvey P.D., Palmer B.W., Heaton R.K., Mohamed S., Kennedy J., Brickman A. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry 2005, 162:110-117.
32. Temkin N.R., Heaton R.K., Grant I., Dikmen S.S. Detecting significant change in neuropsychological test performance: a comparison of four models. J Int Neuropsychol Soc 1999, 5:357-369.
33. McClelland G.R. The effects of practice on measures of performance. Hum Psychopharmacol 1987, 2:109-118.
34. Duff K., Westervelt H.J., McCaffrey R.J., Haase R.F. Practice effects, test-retest stability, and dual baseline assessments with the California Verbal Learning Test in an HIV sample. Arch Clin Neuropsychol 2001, 16:461-476.
35. Collie A., Maruff P., Darby D.G., McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003, 9:419-428.
36. Falleti M.G., Maruff P., Collie A., Darby D.G. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol 2006, 28:1095-1112.
37. Beglinger L.J., Ahmed S., Derby M.A., Siemers E., Fastenau P.S., Crawford-Miller J., et al. Neuropsychological practice effects and change detection in people with schizophrenia. Schizophr Res 2003, 62:191-194.
38. Vinogradov S., Fisher M., de Villers-Sidani E. Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology 2012, 37:43-76.
39. Pietrzak R.H., Maruff P., Snyder P.J. Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil. J Nutr Health Aging 2009, 13:268-273.
40. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278.
41. Karantzoulis S., Novitski J., Gold M., Randolph C. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer's disease. Arch Clin Neuropsychol 2013, 28:837-844.
42. Pietrzak R.H., Snyder P.J., Jackson C.E., Olver J., Norman T., Piskulic D., et al. Stability of cognitive impairment in chronic schizophrenia over brief and intermediate re-test intervals. Hum Psychopharmacol 2009, 24:113-121.
43. Pietrzak R.H., Olver J., Norman T., Piskulic D., Maruff P., Snyder P.J. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 2009, 31:848-859.
44. Maruff P., Thomas E., Cysique L., Brew B., Collie A., Snyder P., et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009, 24:165-178.
45. Allain H., Neuman E., Malbezin M., Salzman V., Guez D., Wesnes K., et al. Bridging study of S12024 in 53 in-patients with Alzheimer's disease. J Am Geriatr Soc 1997, 45:125-126.
46. Vellas B., Cunha L., Gertz H.J., De Deyn P.P., Wesnes K., Hammond G., et al. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Curr Med Res Opin 2005, 21:1423-1429.
47. Galvin J.E., Cornblatt B., Newhouse P., Ancoli-Israel S., Wesnes K., Williamson D., et al. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord 2008, 22:30-38.
48. Wesnes K., Edgar C., Andreasen N., Annas P., Basun H., Lannfelt L., et al. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurol Scand 2010, 122:270-277.